Skip to main content

Home/ Dr. Goodyear/ Group items tagged intramuscular

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrins... - 0 views

ajpgi.physiology.org/...G269

BCAA branched chain amino acids NH3 ammonia liver disease cirrhosis alpha-ketoglutarate

shared by Nathan Goodyear on 10 Feb 14 - No Cached
  • Nathan Goodyear on 10 Feb 14
     
    Good review of the effects of BCAA on ammonia metabolism.  BCAA increase intramuscular NH3 production through the production of alpha-ketoglutarate.
Nathan Goodyear

Efficacy and tolerability of oral and intramuscular S-adenosyl- l-methionine 1,4-butane... - 0 views

www.ajcn.org/...1172S.full

SAMe depression major depression

shared by Nathan Goodyear on 25 Jun 12 - No Cached
  • Nathan Goodyear on 25 Jun 12
     
    Head to head study of SAMe and imipramine for major depression found SAMe to be equivalent in efficacy to imipramine, but with fewer side effects.
Nathan Goodyear

Fifteen years of experience with intramuscular testosterone undecanoate for substitutio... - 0 views

www.endocrine-abstracts.org/...ea0032P652.htm

Testosterone metabolic syndrome metabolic syndrome MetS men male hormones hormone PSA prostate low T

shared by Nathan Goodyear on 13 Mar 14 - No Cached
  • Nathan Goodyear on 13 Mar 14
     
    Abstract presented finds that Testosterone IM undecanoate significantly reduced metabolic syndrome parameters in men.  This study looked at men with secondary hypogonadism and late onset.  The ages were from 15-72.  The full is not available as of this post.  The study only looked at serum T.  This limits the usefulness of this test.  According to this abstract, no evaluation of SHBG was performed.  Though not significant, PSA and prostate volume increased.
Nathan Goodyear

Long-Term Bioavailability After a Single Oral or Intramuscular Administration of 600,00... - 0 views

jcem.endojournals.org/...2709.abstract

Vitamin D D3 vitamin 25-OH D

shared by Nathan Goodyear on 22 Jul 13 - No Cached
  • Nathan Goodyear on 22 Jul 13
     
    This study is misleading.  Their conclusion is that D2 and D3 are equivalent in raising 25-OH vitamin D via po form preferentially over the IM form. However, when you look at the results, the response of D3 was statistically significant over that of D2.  That is the conclusion: vitamin D3 is the optimal form of vitamin D.
Nathan Goodyear

Concomitant intramuscular human chorionic gonadotropi... [J Urol. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...23260550

HCG low t low testosterone low t Testosterone men male hormone hormones human chorionic gonadotropin hypogonadism replacement

shared by Nathan Goodyear on 03 Aug 14 - No Cached
  • Nathan Goodyear on 03 Aug 14
     
    I can't say I agree with the premise of the study design.  In this study, HCG at 500 IU every other day was used to aid Testosterone therapy.  
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC5686300

nagalase Gc-MAF cancer

shared by Nathan Goodyear on 29 Jan 18 - No Cached
  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  • Nathan Goodyear on 29 Jan 18
     
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
1 - 8 of 8
Showing 20▼ items per page